3
|
Ozcelik M, Odabas H, Ercelep O, Yuksel S, Mert AG, Aydin D, Surmeli H, Isik D, Isik S, Oyman A, Oven Ustaalioglu BB, Aliustaoglu M, Gumus M. The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clin Transl Oncol 2015; 18:617-24. [PMID: 26459249 DOI: 10.1007/s12094-015-1408-6] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Accepted: 09/05/2015] [Indexed: 11/24/2022]
Abstract
AIM The optimal treatment in older persons with metastatic colorectal cancer (mCRC) is complicated by a lack of general agreement. The aim of this study was to evaluate the activity of bevacizumab plus capecitabine combination in elderly mCRC patients who were not suitable for chemotherapy with irinotecan and oxaliplatin-containing regimens. MATERIALS AND METHODS Seventy years and older patients with metastatic colorectal carcinoma were included in this retrospective study. Bevacizumab was administered at a dose of 7.5 mg/kg on day 1 as an intravenous (IV) infusion over 30-90 min every 21 days, and capecitabine was prescribed at 1000 mg/m(2) twice daily on days 1-14 of the same 21-day schedule. RESULTS Eighty-two consecutive patients (47 men, 35 women) were included in the study. The mean age was 75.5 (SD 3.9, range 70-87). Half of the patients were older than 75 years. There were 55 patients (67.1 %) with a good Eastern Cooperative Oncology Group (ECOG) performance status (PS: 0-1) and the remaining 27 patients (32.9 %) had a poor ECOG performance status (PS: 2). With a median follow-up period of 18.5 months, the median progression-free survival (PFS) was 10 months (95 % CI, 7.8-12.1) and the median OS was 25 months (95 % CI, 18.6-31.3). The main toxicities recorded were non-hematological. Thirty-one patients (37 %) experienced grade 3/4 adverse events, the most common being hand-foot syndrome (9.8 %). No fatal toxicity resulting from this regimen was recorded. CONCLUSIONS Considering the toxicity profile and survival outcomes, the combination regimen of capecitabine and bevacizumab is a potentially feasible treatment option in elderly mCRC patients.
Collapse
Affiliation(s)
- M Ozcelik
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey.
| | - H Odabas
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - O Ercelep
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - S Yuksel
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - A G Mert
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - D Aydin
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - H Surmeli
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - D Isik
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - S Isik
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - A Oyman
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - B B Oven Ustaalioglu
- Department of Medical Oncology, Haydarpasa Numune Education and Research Hospital, 34668, Istanbul, Turkey
| | - M Aliustaoglu
- Department of Medical Oncology, Kartal Dr. Lutfi Kirdar Education and Research Hospital, 34865, Istanbul, Turkey
| | - M Gumus
- Department of Medical Oncology, Bezmialem Vakif University School of Medicine, 34093, Istanbul, Turkey
| |
Collapse
|
4
|
Anisimov VN, Khavinson VK, Mikhailova ON. Biogerontology in Russia: from past to future. Biogerontology 2010; 12:47-60. [PMID: 21053075 DOI: 10.1007/s10522-010-9307-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2010] [Accepted: 10/19/2010] [Indexed: 10/18/2022]
Abstract
The paper presents major steps of gerontology development in Russia. The issues of training in gerontology and geriatrics, institutional infrastructure within the Gerontological Society of the Russian Academy of Sciences and its activities have been considered therein. Some results of Russian researchers obtained during 2005-2010 have been summarized as well. Special attention is given to the prospects of gerontology in Russia.
Collapse
Affiliation(s)
- Vladimir N Anisimov
- Gerontological Society of the Russian Academy of Sciences, St. Petersburg, Russia.
| | | | | |
Collapse
|